Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
| Business Activity | PASS |
| Debt Ratio | N/A |
| Cash Ratio | N/A |
| Receivables Ratio | N/A |
| Revenue Ratio | N/A |
| Overall | INSUFFICIENT DATA |
$4.8B
4.61
0.692
16
$8.0M
1.42
14.63
0.2%
261
| Shares | Cost | Profit to Target | R:R |
|---|---|---|---|
| To Consensus ($118.47, 17 analysts) | |||
| 10 | $777.50 | +$407.20 (52%) | 3.5R |
| 50 | $3,887.50 | +$2,036.00 (52%) | 3.5R |
| 100 | $7,775.00 | +$4,072.00 (52%) | 3.5R |
- Elevated short interest (14.63 days to cover)
A single score combining all analytical layers below. A is strongest, D is weakest.
How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.
Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.
What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?
Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.
Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.
These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.
| Ticker | Correlation |
|---|---|
| SYRE | 0.503 |
| ARKG | 0.469 |
| IWM | 0.447 |
| CLDX | 0.439 |
| XNCR | 0.435 |
| Ticker | Correlation |
|---|---|
| BAES.L | -0.150 |
| NCCI.KW | -0.144 |
| AGILQ | -0.142 |
| SPI.L | -0.131 |
| GDWN.L | -0.128 |
Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.
How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.